Case Studies

Medialis has supported clients promoting a medicines for the treatment of type 2 diabetes, XLH, cancer, cardiac and neurological disorders and a variety of rare diseases

Medialis differentiated the Fentanyl Buccal Tablet within the Rapid Onset Opioid Class

Medialis assessed the data and selected a systematic review and network meta analysis to model the expected performance of the client’s product against its competitors.

Medialis differentiated Incobotulinum toxin within the botulinum toxin class

In a primarily privately funded sector, the key to understanding if there were any differences between the three toxins was to link this to the cost of treatment.

We use cookies to give you the best possible experience. By using our website, you're agreeing to our use of cookies. To find out more read our cookie policy